Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250486 | 0.85 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL25520998 | 0.85 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1560459 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1139919 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31035756 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL25417788 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1139920 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL17522170 | 0.83 | KDM1A (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL22283784 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL17808583 | 0.83 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097230-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |